长春瑞滨联合卡培他滨治疗晚期乳癌临床观察  

Clinical Observation of Vinorelbine Combined with Capecitabine for Advanced Breast Cancer

作　　者：彭培建[1] 张红雨[1] 林忠[1] 肖妹[1] 陈楠[1] 

机构地区：[1]中山大学附属第五医院肿瘤化疗科,广东省珠海市519000

出　　处：《中华全科医学》2009年第11期1164-1164,1228,共2页Chinese Journal of General Practice

摘　　要：目的观察长春瑞滨联合卡培他滨治疗晚期乳腺癌的临床疗效和毒副反应。方法长春瑞滨25mg/m2快速静脉滴注,第1,8天;卡培他滨1000mg/m2,2次/d,第1～14天,21d为一周期,所有病例均接受至少2个周期的化疗。结果28例患者入组,均为复治病例,均可行疗效及毒性评价,其中完全缓解1例(3.6%),部分缓解12例(42.8%),总有效率46.4%。主要毒副反应为骨髓毒性及手足综合症,均相对较轻。结论长春瑞滨联合卡培他滨方案治疗晚期乳腺癌有较好的疗效,毒副反应小,值得临床进一步研究。Objective To investigate the efficacy and toxicity of Vinorelbine（NVB） combined with Capecitabine in the treatment of advanced breast cancer. Methods Vinorelbine 25 mg/m^2 rapid infusion on days 1,8 ,and oral Capecitabine 1 000 nag/ m^2 twice daily for 14 days were administered every three weeks. All patients received at least two cycles of the treatment. Results Twenty-eight patients were enrolled and were treated previously. All patients were included in the efficacy and adverse events analysis. There were 1 case complete response （3.6%）, 12 partial responses （42.8%）, giving an overall response rate of 46.4%. The major toxicity included myelotoxicity and hand-foot syndrome and were generally mild. Conclusion Vinorelbine combined with Capcitabine demonstrates clinical activity and an acceptable safety profile in patients with advanced breast cancer. Further investigation is warranted.

关 键 词：长春瑞滨 卡培他滨 化学疗法 乳腺肿瘤 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]